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Abstract
The α7-nicotinic acetylcholine receptor (α7-nAChR) is a ligand-gated ion channel that is 
expressed widely in vertebrates and is the principal high-affnity α-bungarotoxin (α-bgtx) binding 
protein in the mammalian CNS. α7-nAChRs associate with proteins that can modulate its 
properties. The α7-nAChR interactome is the summation of proteins interacting or associating 
with α7-nAChRs in a protein complex. To identify an α7-nAChR interactome in neural tissue, we 
isolated α-bgtx-affnity protein complexes from wild-type and α7-nAChR knockout (α7 KO) 
mouse whole brain tissue homogenates using α-bgtx-affnity beads. Affnity precipitated proteins 
were trypsinized and analyzed with an Orbitrap Fusion mass spectrometer. Proteins isolated with 
the α7-nAChR specific ligand, α-bgtx, were determined to be α7-nAChR associated proteins. The 
α7-nAChR subunit and 120 additional proteins were identified. Additionally, 369 proteins were 
identified as binding to α-bgtx in the absence of α7-nAChR expression, thereby identifying 
nonspecific proteins for α7-nAChR investigations using α-bgtx enrichment. These results expand 
on our previous investigations of α7-nAChR interacting proteins using α-bgtx-affnity bead 
isolation by controlling for differences between α7-nAChR and α-bgtx-specific proteins, 
developing an improved protein isolation methodology, and incorporating the latest technology in 
mass spectrometry. The α7-nAChR interactome identified in this study includes proteins 
associated with the expression, localization, function, or modulation of α7-nAChRs, and it 
*Corresponding Author mmulcahy@caltech.edu. Phone: 626-395-4932.¶Present Address M.J.M.: Currently works at Division of Biology and Biological Engineering, California Institute of Technology, 
Pasadena CA 91125-2900, United States. Experimental work by M.J.M. was done at the Department of Molecular Pharmacology, 
Physiology and Biotechnology, Brown University, Providence, Rhode Island 02912, United States.
Author Contributions
The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript. 
M.J.M, J.A.P., and E.H. conceived and designed experiments; M.J.M. and J.A.P. performed the experiments; J.A.P. and E.H. 
contributed reagents/materials/ analysis tools; M.J.M. wrote the manuscript; and M.J.M., J.A.P., and E.H. edited the manuscript.
Notes
The authors declare no competing financial interest.
ASSOCIATED CONTENT
Supporting Information
The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.jproteome.8b00618.
HHS Public Access
Author manuscript
J Proteome Res. Author manuscript; available in PMC 2018 December 20.
Published in final edited form as:
J Proteome Res. 2018 November 02; 17(11): 3959–3975. doi:10.1021/acs.jproteome.8b00618.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
provides a foundation for future studies to elucidate how these interactions contribute to human 
disease.
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INTRODUCTION
The ligand-gated ion channel (LGIC) superfamily comprises a diverse array of structurally 
similar ionotropic receptors, including nicotinic acetylcholine, γ-aminobutyric acid 
(GABA)A, GABAC, glycine, and 5-HT3 serotonin receptors.1,2 Nicotinic acetylcholine 
receptors (nAChRs) are pentameric cation channels expressed widely in the mammalian 
brain and neuromuscular junction.3 Neuronal-type nAChRs are also found in several non-
neuronal cell types, including leukocytes.4 Eleven neuronal nAChR subunits have been 
identified in mammals (α2–7, α9–10, β2–4).5 Receptors containing α4β2, α3β4, and α7 
subunits are the most prevalent in the mammalian CNS, with α7-nAChRs being the most 
widely expressed homomeric nAChR.3 The α7-nAChR, composed of five α7 subunits, has 
several unique physiological traits distinguishing it from other receptor subtypes. For 
example, the α7-nAChR has a higher Ca2+:Na+ permeability ratio than other nAChR 
subtypes, suggesting a greater physiological role in Ca2+ signaling pathways.1,6
The investigation of α7-nAChRs has been facilitated by the availability of several high-
affnity, selective ligands, including α-bungarotoxin (α-bgtx) and methyllycaconitine (MLA). 
Radiolabeled α-bgtx and MLA binding in murine brain tissue has been used extensively to 
establish α7-nAChR levels and distribution.7,8 Studies using 125I-α-bgtx have investigated 
changes in α7-nAChR expression during development, as well as drug-induced changes in 
α7-nAChR expression in whole brain and specific brain regions.9,10 Interstrain variability of 
α7-nAChR levels and distribution has also been investigated using radiolabeled α-bgtx.11 α-
Bgtx is well-characterized as having high-affnity (nM Kd) for α7-nAChRs, and as such is a 
reliable, commercially available ligand for affnity purification of α7-nAChRs.
Proteins associating with a target of interest, in our case α7-nAChR, are collectively known 
as an interactome. Receptor interactomes may include both direct interactions with the 
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receptor and indirect interactions with the receptor-protein complex. Certain receptor-protein 
interactions regulate receptor biogenesis and function. These protein interactions may 
impact α7-nAChR assembly,12 affect traffcking and targeting,13,14 contribute to signaling,15 
and/or be medically relevant.16,17 Mass spectrometry-based protein identification is a well-
established and valuable tool for determining protein interactomes.18,19
The murine brain is an ideal model for the investigation of α7-nAChR interacting proteins, 
as various strains and genotypes are readily available for study, and technologies to establish 
new transgenic and mutant mouse models have been developed. The described work 
expands on prior proteomic studies using α-bgtx as a tool for affnity purification of α7-
nAChRs. Here, we incorporate several new methods enabling the reliable detection of 
murine α7-nAChRs and associated proteins, and we explore both α7-nAChR and α-bgtx-
specific protein controls.20
Several proteomic comparisons are described in our investigation. The first comparison is an 
analysis of α-bgtx-affnity purified proteins from wild-type and α7 KO mice. This 
comparison allows identification of α7-nAChR specific interacting proteins. The second 
comparison is an analysis of proteins that bind to α-bgtx in the absence of α7-nAChRs, 
using α7 KO mice to identify those proteins that do not interact with α7-nAChRs, but that 
do interact with α-bgtx-affnity beads. The GABAA receptor (GABAAR) has recently been 
shown to have affnity for α-bgtx in mouse tissue.21 Given this, the use of α7-nAChR-
specific controls, rather than α-bgtx-specific controls, is of paramount importance for 
proteomic investigations when using α-bgtx-affnity purification to exclude non-α7-nAChR, 
α-bgtx interacting proteins. Some of the previously reported α7-nAChR associated proteins 
may, in fact, associate with another α-bgtx-affnity protein and not with the α7-nAChR.
In summary, the work described here defines a murine whole brain α7-nAChR interactome, 
while also identifying the receptor subunit itself. Additionally, the availability of α7 KO 
mice and α-bgtx immobilization techniques allows for the identification of α-bgtx-affnity 
proteins that should not be included in the α7-nAChR interactome.
EXPERIMENTAL SECTION
Mouse Brain Tissue
Whole brains of adult, male, wild-type C57Bl/6 or FVB mice, as well as adult, male, α7 KO 
FVB mice, were isolated and frozen at −80 °C before use. All protocols were approved by 
the Institutional Animal Care and Use Committee of Brown University (protocol 1201004).
Preparation of α-bgtx-Sepharose Affnity Beads
Cyanogen bromide-activated Sepharose beads 4B (Sigma-Aldrich, St. Louis, MO) (1g) were 
hydrated in 5 mL of cold 1 mM HCl for 30 min and washed with 500 mL of 1 mM HCl over 
a coarse glass filter. The beads were added to 7.5 mL coupling buffer (0.25 M NaHCO3, 0.5 
M NaCl, pH 8.3) and subsequently centrifuged at 4 °C for 5 min at 1500g. The supernatant 
was discarded, and the pellets were resuspended in 7.5 mL coupling buffer containing 4 mg 
of α-bgtx (0.53 mg α-bgtx/ml coupling buffer/g Sepharose 4B beads). Bead/ligand mixtures 
were incubated with gentle agitation at 4 °C for 18 h. The beads were subsequently pelleted 
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and resuspended in 7.5 mL of 0.2 M glycine in 80% coupling buffer and 20% ultrapure 
water, and they were gently agitated overnight at 4 °C to block unreacted groups on the 
beads. The beads were then washed over a coarse glass filter, first with 100 mL of 0.1 M 
NaHCO3, 0.5 M NaCl, pH 8.0, then 100 mL of 0.1 M NaCH3CO2, 0.5 M NaCl, pH 4.0, 
again with 100 mL of 0.1 M NaHCO3, 0.5 M NaCl, pH 8.0, 100 mL coupling buffer, and 
last twice with 100 mL Tris-buffered saline (TBS: 150 mM NaCl, 50 mM Tris, pH 7.5). 
Washed beads were resuspended in TBS for storage at 4 °C. Prior to use, stock α-bgtx-
affnity beads were uniformly resuspended into a slurry, and aliquots were centrifuged at 
4 °C for 5 min at 1500g. Pelleted beads were resuspended to make a 50/50 slurry with 
homogenization buffer (50 mM NaCl, 50 mM NaH2PO4, 2 mM EDTA, 2 mM EGTA, pH 
7.4) before use.
Mouse Whole Brain Membrane Protein Solubilization
Mouse whole brains were dissociated in homogenization buffer (50 mM NaCl, 50 mM 
NaH2PO4, 2 mM EDTA, 2 mM EGTA, pH 7.4) with 30 strokes of a Potter-Elvehjem glass 
homogenizer on ice. Membrane fragments were isolated following centrifugation at 97 000g 
for 60 min at 4 °C. Membrane pellets were then treated with solubilization buffer (50 mM 
NaCl, 50 mM NaH2PO4, 2 mM EDTA, 2 mM EGTA, 2% Triton X-100, pH 7.4) with 40 
strokes of a Potter-Elvehjem glass homogenizer on ice and incubated for 3 h at 4 °C with 
agitation to solubilize membrane-bound proteins. Following a second centrifugation at 100 
000g for 60 min at 4 °C, the solubilized membrane fraction was recovered in the 
supernatant. All buffers used to isolate the solubilized membrane fraction were 
supplemented with protease inhibitors (Roche, Basel, Switzerland). Protein content of 
solubilized membrane fractions was determined using a bicinchoninic acid (BCA) assay 
(Pierce, Waltham, MA).
α7-nAChR and Associated Protein Complex Isolation
Immediately following the isolation of solubilized membrane fractions, a volume containing 
25 mg of solubilized protein was incubated with 200 μL of the 50/50 α-bgtx-affnity bead/ 
homogenization buffer slurry for 18 h at 4 °C with gentle agitation. α-Bgtx-affnity beads 
were washed with homogenization buffer before use. Control samples were either 
solubilized receptor preparations from α7 KO mice (i.e., α7-nAChR-specific control) or 
control beads lacking conjugated α-bgtx (i.e., α-bgtx-specific control) (Figure 1). Following 
the incubation, α-bgtx-affnity beads and bound protein were transferred to Pierce Spin Cups 
(Thermo Fisher Scientific Inc., Waltham, MA) and washed three times with solubilization 
buffer. After the beads and bound protein were washed, the total affnity-immobilized α7-
nAChR content was either measured using a 125I-α-bgtx radioligand binding assay, or the 
isolated proteins were eluted for mass spectrometry analysis (Figure 2).
Radioligand Binding Assays
An on-bead 125I-α-bgtx binding assay was used to confirm α7-nAChR presence on α-bgtx-
affnity beads and the absence of α7-nAChRs on control beads. α-Bgtx is able to affnity 
immobilize and concurrently detect α7-nAChRs, as these receptors contain multiple α-bgtx 
binding sites.22 Affnity-immobilized α7-nAChR content was determined by incubating 
samples with 5 nM 125I-α-bgtx (PerkinElmer, Boston, MA) for 1 h at room temperature. 
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Nonspecific binding was determined in controls by the inclusion of 1 μM unlabeled α-bgtx 
prior to addition of 125I-α-bgtx. Following incubation with 125I-α-bgtx, beads were washed 
three times with solubilization buffer and gamma emissions were measured using a Wallac 
1275 minigamma gamma counter.
Mass Spectrometry Sample Preparation, Precipitation, and In-Solution Trypsin Digestion
Affnity beads were washed three times with solubilization buffer followed by a single, high-
salt solubilization buffer wash (2.05 M NaCl, 50 mM NaH2PO4, 2 mM EDTA, 2 mM 
EGTA, 2% Triton X-100, pH 7.4) to enhance the identification of α7-nAChR by eluting 
non-α7-nAChR protein from the affnity beads. Immobilized α7-nAChR protein complexes 
were specifically eluted from the α-bgtx-affnity beads by incubation with 100 μL 1 M 
carbachol (Sigma-Aldrich, St. Louis, MO) in 20 mM HEPES, pH 8.0 for 30 min with 
agitation every 5 min at room temperature. α-Bgtx-affnity beads were allowed to sediment, 
and the eluted proteins in the supernatant were removed and stored at −80 °C until 
preparation for mass spectrometry analysis. The quantity of eluted protein was determined 
using the Pierce BCA Protein Assay Kit. To prepare for mass spectrometric analysis, 
samples were thawed and disulfide residues were reduced with 47 mM TCEP in 20 mM 
HEPES, pH 8.0 for 1 h at 60 °C. Samples were alkylated with 83 mM iodoacetamide in 20 
mM HEPES, pH 8.0 for 1 h in the dark at room temperature, and then concentrated and 
purified via precipitation using a BioRad ReadyPrep 2-D Cleanup Kit (BioRad, Hercules, 
CA). Precipitated protein was resuspended in 50 mM ammonium bicarbonate, pH 7.8 
supplemented with 100 ng trypsin (Promega, Madison, WI) and digested overnight in-
solution at 37 °C. Both high-salt solubilization buffer washes and 1 M carbachol elutions 
were analyzed using mass spectrometry.
HPLC and Mass Spectrometry Analysis
Each sample was desalted using a StageTip and dried via vacuum centrifugation. Peptides 
were reconstituted in 5% acetonitrile (ACN), 5% formic acid for LC-MS/MS analysis using 
an Orbitrap Fusion mass spectrometer (Thermo Fisher Scientific, San Jose, CA) coupled to 
an in-line Proxeon EASY-nLC 1000 liquid chromatography (LC) pump (Thermo Fisher 
Scientific, San Jose, CA). Peptides (approximately 2 μg) were fractionated on a 
microcapillary column (75 μm inner diameter) packed with ∼0.5 cm of Magic C4 resin (5 
μm, 100 Å, Michrom Bioresources) followed by ∼35 cm of GP-18 resin (1.8 μm, 200 Å, 
Sepax, Newark, DE). Separation of peptides was achieved during a 3 h gradient of 6 to 26% 
ACN in 0.125% formic acid at a rate of 350 nL/min. The scan sequence began with an MS1 
spectrum (Orbitrap analysis; resolution 120 000; mass range 400–1400 m/z; automatic gain 
control (AGC) target 2 × 105; maximum injection time 100 ms). Precursor ion selection for 
MS/MS analysis was performed using a TopSpeed of 2 s or TopN of 20 ions. MS/MS 
analysis consisted of collision-induced dissociation (CID) (quadrupole ion trap analysis; 
automatic gain control (AGC) 1 × 104; normalized collision energy (NCE) 35; maximum 
injection time 150 ms). Peak lists of MS/MS spectra were created using msconvert.exe (v. 
2.2.3300) available in the ProteoWizard tool.23 Experimental spectra were bioinformatically 
matched in silico against theoretical spectra of a concatenated target-decoy (sequence-
reversed) Mus musculus database (Uniprot, March 2015) using the Mascot algorithm 
(Matrix Science, Boston, MA). Database searches used the following parameters: up to two 
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missed trypsin cleaves allowed, 7 ppm MS tolerance, 20 ppm MS/MS tolerance, fixed 
carbamidomethyl modification, and variable methionine oxidation modification.
Data Analysis
Mascot search results were loaded into ProteoIQ (Premier Biosoft, Palo Alto, CA) for 
further analysis. All identified proteins were initially filtered using a 1% protein false-
discovery rate (FDR) calculated with the PROVALT algorithm and a minimum peptide 
length of six amino acids. Inclusion criteria for α7-nAChR and α-bgtx interacting proteins 
were as follows: ≥ 90% group probability score of correct identity assignment using the 
ProteinProphet algorithm, presence in two or more independent replicates, and 0% 
probability score in controls.24–26 Both the PROVALT and ProteinProphet algorithm are 
integrated into ProteoIQ. Only Top and Co-Top identifications (i.e., identifications that 
include all peptide data in a protein group) were used during analysis. For mass 
spectrometry analysis, each condition was analyzed with five biological replicates. Identified 
α7-nAChR-specific interacting proteins were categorized by their reported Gene Ontology 
(GO) biological process and cellular compartment terms using Search Tool for Recurring 
Instances of Neighboring Genes (STRING) (version 10.5), and Database for Annotation, 
Visualization and Integrated Discovery (DAVID) (version 6.8).27,28 If neither classification 
system had an entry for an identified protein, the protein was classified as unattributed. 
STRING was used to visualize interactomes, analyze possible GO Term enrichments for 
cellular compartment, molecular function or biological process, as well as illustrate known 
connections between identified interacting proteins.28 FDRs for enriched ontologies were 
reported using STRING analysis. DAVID was used to identify ontologies represented in the 
identified proteomes that may not be enriched. Results from DAVID were reported as p-
values using the Benjamini–Hochberg procedure for correcting multiple comparisons.
RESULTS AND DISCUSSION
Immobilization of α7-nAChRs and Associated Proteins Using α-bgtx-Affnity Beads
Solubilized C57Bl/6 and FVB murine brain tissue preparations from both wild-type and α7 
KO FVB controls were incubated with α-bgtx-affnity beads or control beads lacking 
conjugated α-bgtx. Using the optimized α-bgtx-affnity immobilization conditions, 5.4 ± 0.5 
fmol 125I-α-bgtx binding per mg solubilized protein was measured in samples from C57Bl/6 
mouse tissue and no observable binding was detected using control beads (Figure 3A). In 
wild-type preparations of FVB mouse brain tissue, 6.4 ± 1 fmol 125I-α-bgtx binding per mg 
solubilized protein was measured, and no detectable binding was observed using α7 KO 
preparations or when incubating wild-type tissue with control beads (Figure 3B).
A primary aim for this work was to establish methods for identifying α7-nAChR peptides, 
as well as providing an updated and well-controlled α7-nAChR interactome from mouse 
brain tissue using α-bgtx-affnity immobilization and mass spectrometry. To achieve this 
aim, several methodological changes were made to our previous study design.20 In addition 
to the changes in homogenization/solubilization and bead conditions, a stringent “high-salt 
wash” (2 M NaCl, 50 mM NaH2PO4, 2 mM EDTA, 2 mM EGTA, 2% Triton X-100, pH 7.4) 
was included prior to elution with carbachol to reduce nonspecific binding to beads. High-
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salt washes did not reduce α-bgtx binding to immobilized α7-nAChRs in the SH-SY5Y 
neuroblastoma-derived cell line that endogenously expresses α7-nAChRs (Supplemental 
Figure S-1).29 However, as 2 M NaCl could displace some protein interactions, the high-salt 
washes were also analyzed by mass spectrometry. For both the α7-nAChR and non-α7-
nAChR, α-bgtx interactomes, the distinction was made between proteins that were eluted in 
the high-salt wash and proteins that were eluted by carbachol. A second α-bgtx interactome, 
only including proteins eluted with carbachol in wild-type tissue, was also investigated.
Identification of α7-nAChR Subunit Peptides and α7-nAChR Interacting Proteins
Comparing α-bgtx purified proteins from wild-type tissue with proteins purified from α7 
KO tissue allowed identification of an α7-nAChR-specific interactome. Proteins from both 
experimental and negative control samples were removed sequentially by a high-salt wash, 
followed by carbachol elution. Fifty-two α7-nAChR interacting proteins were eluted with 
carbachol, including a peptide of the α7-nAChR subunit, FPDGQIWKPDILLYNSADER 
(Table 1, Supplemental Tables S-1). Seventy α7-nAChR interacting proteins were identified 
in high-salt washes. An interactome of 121 α7-nAChR interacting proteins was identified by 
combining identifications from both high-salt washes and carbachol elutions (Figure 4A). 
Peptides from α7 subunits were not identified in high-salt washes (Supplemental Tables 
S-1). A single protein, plakophilin-1, was identified in both the high-salt washes and 
carbachol-eluted fractions. Proteins identified as α7-nAChR interacting proteins in high-salt 
washes (i.e., not identified in α7 KO control samples) were not included in the α7 
interactome if the protein was subsequently identified in both experimental and α7 KO 
controls after carbachol elution.
Several studies have previously investigated α7-nAChR interactomes using mass 
spectrometry.20,30,31 Paulo et al. first utilized α-bgtx-affnity beads to isolate protein 
complexes from wild-type and α7 KO mice to investigate the α7-nAChR interactome.20 
While the methodology used in the Paulo et al. study is similar to that used here, no peptides 
originating from the α7-nAChR subunit were identified by mass spectrometric analysis. A 
second study used α-bgtx-affnity to isolate α7-nAChRs and to identify the receptor as well 
as their protein of interest, PMCA2, using rat brain extracts and mass spectrometry.31 
However, this study did not report suffcient details on the identification of α7-nAChR 
peptides and did not utilize an α7-nAChR-specific control for the analysis. More recently, 
α7-nAChR subunit peptides have been identified, along with interacting proteins, in the rat 
pheochromocytoma-derived cell line PC12 using anti-α7-nAChR antibody conjugated 
affnity beads and mass spectrometry.30 Several commercially available antibodies for 
nAChRs have been reported to have inconsistent characteristics, and their use for 
immunoprecipitation can be problematic.32,33 α-Bgtx provides a reliable, commercially 
available ligand for affnity purification of α7-nAChRs.
The sequenced α7-nAChR subunit peptide, FPDGQ-IWKPDILLYNSADER, was identified 
in wild-type samples of both FVB and C57Bl/6 mice and was not identified in either α7-
nAChR-specific and α-bgtx-specific controls (Table 1, Supplemental Tables S-1, S-8). The 
same peptide was identified previously in SH-SY5Y samples (not shown) and in transfected 
SH-EP1 cells, two human neuroblastoma-derived cell models of α7-nAChR expression.34 In 
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addition to identifying α7-nAChRs, GABAAR subunits, recently shown to bind α-bgtx, 
were identified in both α-bgtx and non-α7-nAChR, α-bgtx interactomes, but not in the α7-
nAChR interactome (Table 1).21,35 This observation stresses the importance of controls that 
are α7-nAChR-specific when using α-bgtx-affnity immobilization.
The proteins of the α7-nAChR interactome were characterized by their known or predicted 
cellular compartments (Supplemental Tables S-2, S-3), molecular functions (Supplemental 
Tables S-4, S-5), and biological processes, using both STRING and DAVID. Interactome 
associated Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were identified 
using DAVID. STRING is useful for highlighting enriched protein characteristics in a 
proteome, whereas DAVID is useful for highlighting proteins of a particular characteristic, 
whether enriched or not. No enriched biological processes were identified by STRING or 
DAVID; though general biological process ontologies were identified by DAVID 
(Supplemental Tables S-6). STRING was used to visualize a protein–protein interaction map 
of the α7-nAChR interactome (Figure 7).
The proteins of the α7-nAChR interactome identified in this study are enriched for cellular 
compartments involved with receptor biogenesis (Golgi-associated vesicle, GO:0005798, 
FDR 0.01), traffcking (cytoplasmic vesicle membrane, GO:0030659, FDR 0.009), the 
receptor’s site of physiological activity (plasma membrane, GO:0005886, FDR 0.008), and 
receptor turnover (endosome, GO:0005768, FDR 0.012). Interestingly, localization to the 
mitochondria (GO:0005739, FDR 0.0004) was also enriched, agreeing with previous studies 
that identified α7-nAChR function in the mitochondrial membrane.36 Proteins localized in 
neuron projections (GO:0043005, FDR 0.008), including α7 subunits, were also enriched, 
which is consistent with the observation that development of neuron projections (i.e., 
neurites) is mediated by α7-nAChRs (Figure 5, Figure 7).37
The identification of interacting proteins is an important step toward understanding where 
receptors were localized, their associated molecular functions, and how those functions 
contribute to biological processes. This understanding may help elucidate how alterations of 
the receptors’ interactors can lead to or contribute to human disease, as well as help identify 
possible therapeutic targets. STRING and KEGG pathway analysis of the identified α7-
nAChR interactome showed enrichment for several molecular functions of potential 
relevance to human disease (Figure 6, Table 2). STRING and KEGG analysis was 
supplemented by a literature review to explore which α7-nAChR interacting proteins that 
were associated with human diseases, such as Alzheimer’s disease, insulin resistance, and 
Parkinson’s disease in the literature. Thirty-one selected human disease-related proteins 
were identified in the α7-nAChR interactome and are presented in Table 3.
Several of these identified proteins are related to Alzheimer’s disease, which is a progressive 
form of dementia pathologically characterized by extracellular plaques containing β-amyloid 
(Aβ) and intracellular neurofibrillary tangles containing hyperphosphorylated tau proteins.
38,39
 Alzheimer’s disease is also characterized by loss of cholinergic neurons, resulting in a 
reduction of nAChR protein expression. Numerous studies have investigated the connection 
between α7-nAChRs and Alzheimer’s disease.40,41 Activation of α7-nAChRs reduces 
neuroinflammation and is considered neuroprotective against Alzheimer’s disease related 
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toxicities (e.g., Aβ1–42 toxicity).42–44 These observations have led to the pursuit of 
cholinergic therapeutics for the treatment of Alzheimer’s disease.45,46 Proteins associated 
with both Aβ and hyper-phosphorylation of tau proteins, the two major components of 
Alzheimer’s disease pathology, were identified in the α7-nAChR interactome (Table 2, 
Table 3).
One of the molecular function enrichments identified during STRING analysis was tau-
protein kinase activity (GO: 005021, FDR 0.02) (Figure 6, Figure 7). The phosphorylation 
of tau by multiple proteins is a hallmark of Alzheimer’s disease pathology and therefore of 
interest for the study of Alzheimer’s disease. The three interactors identified were 5′-AMP-
activated protein kinase catalytic subunit alpha-1 (Prkaa1), MAP/ microtubule affnity-
regulating kinase 2 (MARK2), and MAP/microtubule affnity-regulating kinase 4 (MARK4). 
Prkaa1 is one of the subunits of 5′-AMP-activated protein kinase (AMPK). AMPK has been 
shown to phosphorylate tau proteins in response to Aβ.47 Two AMPK-related proteins, 
MARK2 and MARK4, were also identified.48 As with AMPK, both MARK2 and MARK4 
have been shown to phosphorylate tau proteins.49 It has also been shown by several groups 
that MARK2 is phosphorylated by glycogen synthase kinase 3β (GSK3β), a principle tau 
kinase, inactivating MARK2.50 We reviewed the literature to identify additional AD related 
proteins that may not be represented in STRING (Table 3). Identified proteins, such as 
insulin-degrading enzyme, that are associated with Alzheimer’s disease but not highlighted 
by STRING analysis may affect the following: (1) interaction with APP or Aβ;51–54 (2) 
altered expression or function in Alzheimer’s disease;55 (3) or have a genetic association.56
The α7-nAChR interactome reported in this study also includes proteins associated with 
insulin sensitivity or resistance,57–62 with changes in gene or protein expression,63 with 
genetic links to diabetes,64 with alteration of biological processes central to diabetes,65,66 or 
with the effects of smoking behavior on diabetes (Table 3).67 STRING analysis of α7-
nAChR interacting proteins identified carbohydrate derivative binding as an enriched 
molecular function (GO: 0097367, FDR 0.02) (Figure 6, Figure 7). The identification of 
proteins associated with both insulin resistance and Alzheimer’s disease is particularly 
interesting as shared similarities exist in some of the abnormal carbohydrate derivative 
sensitivity (e.g., to D-glucose) and metabolic pathways involved in both of these medically 
relevant conditions.68–71 For example, individuals with type 2 diabetes mellitus (i.e., insulin 
resistance) are more susceptible to an increased risk for developing Alzheimer’s disease.
72–74
As with Alzheimer’s disease, neuroprotection mediated by α7-nAChR activation has been 
demonstrated in several models of Parkinson’s disease (PD).75 Stimulation of α7-nAChRs 
can also ameliorate dyskinesia in models of Parkinson’s disease.76,77 Several proteins in the 
α7-nAChR interactome reported in this study are genetically associated with certain 
populations of patients with Parkinson’s disease (Table 3).78,79 Additionally certain proteins 
in the α7-nAChR interactome have altered expression levels in PD patients, such as ATP5J, 
a component of a mitochondrial ATP synthase (Table 2, Table 3).80 Additional proteins 
identified in this study are associated with neuroprotection against α-synuclein toxicity in 
Parkinson’s disease or are activated by α-synuclein.81,82 Overall, α7-nAChR function may 
be involved in the molecular dysfunction of multiple diseases and the α7-nAChR 
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interactome may therefore be of interest as a potential therapeutic target for the treatment of 
those diseases. Identification of the protein–protein interactions of α7-nAChRs may help us 
understand how the receptor-protein interactions with these ion channels may be involved 
with human disease and may lead to the development of novel therapeutics.
A connection between α7-nAChRs and Alzheimer’s disease from human post-mortem 
studies is undeniable, but the details of the association still need to be clarified. The findings 
presented in this study may be used as a foundation for the study α7-nAChRs using animal 
models of human disease, such as Alzheimer’s disease (AD) rodent models.
An investigation of α7 KO mice crossed with an amyloid precursor protein (APP) 
overexpressing mouse line (“APPα7-KO”) demonstrated that APPα7KO mice demonstrated 
the same levels of APP and Aβ as control APP mice, but did not suffer cognitive defects of 
the same magnitude.83 It has been shown that extracellular Aβ binds α7-nAChRs and 
enhances the internalization of the receptors.17,84 This could increase Aβ intracellularly, 
leading to increased toxicity and possibly cell death. This hypothesis would support the fact 
that while α7 KO mice demonstrate the same levels of APP and Aβ as wild-type mice, 
deletion of α7-nAChRs can reduce Aβ internalization and therefore reduce toxicity resulting 
in reduced cognitive loss. Thus, prevention of α7-nAChR internalization caused by Aβ may 
be a therapeutic target for the alleviation of cognitive decline in AD, not necessarily through 
the prevention of Aβ aggregation, but rather through amelioration of Aβ toxicity.
Fifty-five murine α7-nAChR interacting proteins have been previously reported by Paulo et 
al., 2009, using α-bgtx-affnity protein isolation and mass spectrometry. Comparing the 55 
proteins from this previous study to our present findings: a single protein, gelsolin, was 
identified in both; 6 were not identified in the present study; and the remaining 48 were 
identified in the α7 KO control samples in the present study and therefore were not included 
as α7-nAChR interacting proteins. There were several changes in experimental methods that 
may account for the differences in the proteins identified in this study compared with the 
previous study. These methodological changes were made to increase α7-nAChR isolation 
effciency to address a concern expressed by Paulo et al., 2009, that while immunoblots 
identified the α7 subunit in the carbachol elution from the α-bgtx affnity beads, the subunit 
was not identified using mass spectrometry, despite the identification of α7-nAChR 
interacting proteins.
The general workflow described in the present study is similar to the previous study, with 
changes in experimental methods to increase the effciency of α7-nAChR isolation, including 
changes in α-bgtx levels conjugated to beads (four times the amount used in the previous 
study), in homogenization buffer selection, in trypsin digest (in-gel vs in-solution), and in 
the sensitivity of available mass spectrometry technology. These alterations were made 
specifically to enable the identification of α7-nAChR peptides in α-bgtx-affnity enriched 
samples after analysis using mass spectrometry. Using a protocol similar to Paulo et al., 
2009, 1.5 ± 0.4 fmol 125I-α-bgtx/mg protein was observed. After our modifications, and as 
shown in Figure 3, we were able to isolate >5 fmol 125I-α-bgtx/mg protein. In addition to 
procedural changes, the Orbitrap Fusion mass spectrometer used in the present study is more 
sensitive than the LTQ-Orbitrap mass spectrometer used in the previous study. These 
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methodological changes may have increased our ability to detect proteins as well as the 
nonspecific interactions with α-bgtx-affnity beads. These qualities, while advantageous for 
detecting α7-nAChRs, would also affect proteins in control samples, identifying proteins in 
both that were not detected using the methods in the previous study. The changes made to 
our workflow for our present study did result in the identification of α7-nAChR subunit 
peptide by mass spectrometry.
α-Bungarotoxin Interacting Proteins
In addition to the murine α7-nAChR interactome, we also investigated proteins interacting 
with α-bgtx. To derive meaningful proteomic data from α-bgtx affnity-immobilization, 
appropriate controls must be utilized to identify nonspecific interactions that should be 
excluded from the analysis of the α7-nAChR interactome. In total, 183 proteins were 
identified in the α-bgtx interactome. Of the total of 183 proteins, 7 (4% of the total α-bgtx 
interactome) proteins were identified in both the carbachol-eluted α-bgtx and α7-nAChR 
interactomes. In contrast, 44 (24% of the total α-bgtx interactome) proteins were identified 
in both the α-bgtx interactome and the non-α7-nAChR, α-bgtx interactome (Figure 8). The 
large number of proteins that are shared between the two α-bgtx interactomes, regardless of 
α7-nAChR expression, demonstrates the importance of using appropriate controls. The α-
bgtx interactome was identified in C57Bl/6, whereas the α7-nAChR and non-α7-nAChR, α-
bgtx interactomes were identified in FVB. While strain differences may contribute to 
reduced levels of overlap between interactomes, the 24% of interacting proteins that are still 
identified between the α-bgtx and non-α7-nAChR, α-bgtx interactomes is diffcult to ignore. 
The distinction between α-bgtx-selective and α7-nAChR-selective controls is also important 
as other proteins have recently been reported to bind to α-bgtx in mammalian brain tissue, 
most notably several GABAAR subtypes.21,35
Proteins isolated on α-bgtx-affnity and control beads from α7-nAChR KO samples were 
compared to identify proteins that interacted with α-bgtx in the absence of α7-nAChR 
expression. We identified a total of 369 proteins interacting with α-bgtx in the absence of 
α7-nAChR (192 high-salt wash-eluted, 232 carbachol-eluted, 55 shared in both elutions) 
(Figure 4B, Supplemental Tables S-7). These proteins can therefore be considered as 
possible non-α7-nAChR specific “contaminants” for studies using α-bgtx-affnity to 
investigate α7-nAChR-protein interactions. Our data show that the β1 GABAAR subunit 
was identified in elutions from α-bgtx beads in α7 KO samples (Table 1D). This finding was 
consistent with the identification of the β3 GABAAR subunit from α-bgtx-affnity bead 
versus control bead comparisons in WT mice (Supplemental Tables S-8). Both β1 and β3 
subunits have been associated with GABAARs with affnity for α-bgtx.21,35 Moreover, 
GABAAR peptides were absent in α7-nAChR interactomes. The comparison of carbachol-
eluted proteins from α-bgtx-affnity beads to proteins eluted from control beads identifies 
proteins by α-bgtx-affnity rather than α7-nAChR specificity. Interestingly, the non-α7-
nAChR, α-bgtx-interactome had large overlap (13%) between the high-salt wash elutions 
and carbachol elution fractions compared to the identified α7-nAChR interactome (1% 
overlap) or α-bgtx interactome (1%).
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Two different mouse strains were used in this study. C57Bl/ 6J (“C57Bl/6”) mice, the same 
mouse strain used in our previous investigations, were used to identify the α-bgtx 
interactome.20 FVB/NJ (“FVB”) mice were used in our investigation of the α7-nAChR 
interactome and the non-α7-nAChR, α-bgtx interactome, due to the availability of the α7 
KO genotype in this strain. With the advantage of large litter sizes and zygote pronuclei, 
FVB are often used in transgenic studies.85 As is common when comparing any two mouse 
strains, genetic differences exist between C57 and FVB mice.86These differences could lead 
to deviations in protein levels and the composition of nAChR interacting proteins, although 
no cross-strain comparisons were performed. Several reports suggest that in general, α7 KO 
mice do not present significant changes in physical, neurological, or behavioral phenotype 
compared to wild-type mice; however, several distinct phenotypes have been reported in α7 
KO mice.87–89 Depression-like phenotypes mediated through BDNF-TRKB signaling have 
been shown in α7 KO mice.90 Neuronal TRKB (ntrk2) was identified in this study, 
suggesting that depression-like phenotypes in knockout mice may be caused by the lack of 
interaction between ntrk2 and the α7-nAChR.
CONCLUSIONS
Here we compared the α-bgtx-affnity proteins from both α7-nAChR wild-type and KO 
mouse whole brain tissue to identify both affnity purified α7-nAChR as well as novel 
interacting proteins. This investigation also characterized two additional murine 
interactomes: a total α-bgtx interactome and a non-α7-nAChR, α-bgtx interactome. The 
data presented here expanded upon our previous investigations of α7-nAChR interacting 
proteins using α-bgtx-affnity bead isolation, differentiating between α7-nAChR- and α-
bgtx-specific negative controls, and using the latest mass spectrometry technology.
Including the α7-nAChR subunit, 121 α7-nAChR interacting proteins were identified in this 
study. These interacting proteins were identified in two fractions: a high-salt wash eluted- 
and a carbachol-eluted fraction from the same α-bgtx-affnity immobilized samples. 
Additionally, the two α-bgtx interactomes identified in this work were novel and highlight 
proteins that should be viewed cautiously if using α-bgtx for affnity proteomics when an 
α7-nAChR-specific control is not available.
Using α-bgtx to affnity-immobilize α7-nAChRs provides an alternative to 
immunoprecipitation for isolating α7-nAChRs and its interacting proteins. Many groups 
have reported inconsistencies when using certain nicotinic receptor-specific antibodies, such 
as detecting immunoreactivity in nAChR null models.32,33 Based on these observations, 
using antibodies for nAChR affnity proteomics may lead to inaccurate findings. As such, α-
bgtx may be advantageous because of its well-characterized affnity for both human and 
murine α7-nAChRs.
Affnity purification of α7-nAChRs with α-bgtx is not without diffculties. The toxin’s high 
affnity may prove problematic; thus, elution conditions must be more stringent than those 
needed with antibody methodologies. The issue of selectivity has also been raised with 
several GABAAR subtypes shown to have α-bgtx-affnity. This concern was alleviated by 
using appropriately selected α7-nAChR-specific control groups. We demonstrated that beads 
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without conjugated ligand were not suffcient to achieve α7-nAChR specificity in α-bgtx-
affnity proteomics. This point was highlighted by the identification of GABAAR peptides in 
both α-bgtx inter-actomes, whereas GABAAR peptides were not identified in the α7-
nAChR-specific interactome.
The strategies and data described in this work highlight improvements in methodologies for 
isolating the α7-nAChR and associated protein complexes from the murine whole brain. The 
positive identification in this study of the α7-nAChR subunit, and its associated receptor 
interactome, established a foundation for the investigation of α7-nAChR interacting proteins 
in murine models of human disease. These investigations open new possibilities for 
investigating proteomic alterations in α7-nAChR interacting proteins caused by or 
contributing to specific disease states.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Murine whole brain experimental design. Solubilized protein was isolated from male (A) 
wild-type or (B) α7 KO mice and was incubated with Sepharose α-bgtx-affnity beads or 
Sepharose beads without α-bgtx (i.e., control beads). The α7-nAChR interactome was 
identified using FVB α7 KO extracts as α7-nAChR-specific controls, which were analyzed 
in parallel with FVB wild-type samples. For non-α7-nAChR, α-bgtx interactome 
investigations, proteins were identified from α7 KO FVB mice incubated with α-bgtx-
affnity beads or control beads. For α-bgtx interactome investigations, wild-type C57Bl/6 α-
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bgtx-affnity enrichments were compared to C57Bl/6 extracts incubated with control beads. 
Protein bound to α-bgtx-affnity beads was sequentially eluted with 2 M NaCl sodium 
chloride and 1 M carbachol, reduced, alkylated, and digested with trypsin in-solution. The 
resulting peptides were analyzed with an Orbitrap Fusion mass spectrometer, and spectra 
were identified using the Mascot algorithm. Data were analyzed further using ProteoIQ.
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Figure 2. 
α-bgtx-affnity immobilization conditions. (A) α-Bgtx-sensitive proteins were isolated from 
samples using wild-type mice and α-bgtx-conjugated affnity beads (i.e., α-bgtx beads). (B) 
Nonspecific interactions with α-bgtx beads were identified using α-bgtx binding enrichment 
in samples prepared from α7 KO mice. (C) Sepharose without conjugated α-bgtx (i.e., 
“control beads”) were used to control for nonspecific interactions to Sepharose. (D) 
Sepharose without conjugated α-bgtx (i.e., “control beads”) were used to control for 
nonspecific interactions to Sepharose in α7 KO mice samples.
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Figure 3. 
Specific 125I-α-bgtx binding to solubilized protein isolated from C57Bl/6 and FVB 
solubilized murine brain tissue. Binding of 5 nM 125I-α-bgtx to protein immobilized on α-
bgtx-affnity beads (4 mg α-bgtx per 1g Sepharose) incubated with male C57Bl/6 (A) and 
FVB (B) solubilized murine whole brain membrane fractions. Nonspecific binding was 
determined by the addition of 1 μM unlabeled α-bgtx to preparations prior to the addition of 
125I-α-bgtx. Appreciable 125I-α-bgtx binding was observed in both C57Bl/6 and FVB 
strains (5.4 ± 0.5 and 6.4 ± 1 fmol 125I-α-bgtx per mg solubilized protein respectively). No 
appreciable binding was detected in either strain using control beads (A,B) or α7 KO FVB 
mice using α-bgtx-affnity beads (B). Three mice were used per condition, and extracts from 
each mouse were measured in duplicate. Significance between α-bgtx affnity pulldowns and 
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either control bead or α-bgtx pulldowns from α7 KO was determined using a Student’s t-
test. “*” denotes p < 0.05.
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Figure 4. 
Summary of identified interactomes. Three interactomes were identified and categorized as 
(A) α7-nAChR, (B) non-α7-nAChR, α-bgtx, or (C) α-bgtx interactomes. High-salt wash-
eluted and carbachol-eluted fractions were investigated in (A) and (B). Only carbachol-
eluted proteins were investigated in (C). The high-salt washes were investigated to identify 
interacting proteins eluted before the addition of carbachol. An α7-nAChR subunit peptide 
was identified in the carbachol elutions of the α7-nAChR as well as in the α-bgtx 
interactomes (denoted by the green arrows). Peptides corresponding to α7-nAChR subunit 
were not identified in the high-salt wash fraction of the α7-nAChR interactome, nor in either 
of the non-α7-nAChR interactomes (red arrows). The total number of proteins identified 
using the defined inclusion criteria is listed on the right.
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Figure 5. 
Cellular compartments enriched in the α7-nAChR interactome data identified using 
STRING. Proteins are identified by their gene name. GO Term identification numbers, false 
discovery rates, and individual matched protein names are included in Supplemental Tables 
S-2. Only matched cellular compartment ontologies <5% FDR are shown. Six ontologies 
described further in the text are highlighted in orange: mitochondrion, plasma membrane, 
neuron projection, cytoplasmic vesicle membrane, Golgi-associated vesicle, and endosome.
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Figure 6. 
Molecular functions enriched in the α7-nAChR interactome data identified using STRING. 
Proteins are identified by their gene name. GO term identification numbers, false discovery 
rates, and individual matched protein names are included in Supplemental Tables S-4. Only 
matched molecular function ontologies <5% FDR are shown. Two ontologies, tau (τ)-
protein kinase activity and carbohydrate derivative binding, are highlighted in orange and 
described further in the text.
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Figure 7. 
Analysis of protein–protein interactions using STRING. STRING analysis (https://string-
db.org/) of total identified α7-nAChR interacting proteins. 110 of 121 total proteins had 
suffcient information for STRING analysis. All options for active interaction sources and a 
minimum interaction score of 0.4 were selected. Edge colors represent known interactions 
from curated databases (teal), known interactions determined from experimentation (purple), 
predicted interactions from gene neighborhood (green), predicted interactions from gene 
fusions (red), or predicted interactions from gene co-occurrence (blue). Additional edge 
colors denote associations determined from text mining (yellow), coexpression (black), or 
protein homology (light blue). Node colors representing molecular functions include tau-
protein kinase activity (red) and carbohydrate derivative binding (dark green). Node colors 
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denoting cellular component include: mitochondrion (light green), plasma membrane 
(yellow), neuron projection (teal), cytoplasmic vesicle membrane (gold), endosome (purple), 
and cytoskeleton (blue).
Mulcahy et al. Page 30
J Proteome Res. Author manuscript; available in PMC 2018 December 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 8. 
Comparison of the carbachol eluted proteins from the three identified interactomes. The 
number of α-bgtx interacting proteins identified in the α7-nAChR interactome or the non-
α7-nAChR, α-bgtx interactome. No proteins were identified in both the α7-nAChR and 
non-α7-nAChR, α-bgtx interactomes.
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